Magnuson A, et al. - In this secondary analysis of a prospective longitudinal observational study, researchers assessed the links between frailty and cognition longitudinally in adults aged ≥ 50 years with breast cancer receiving chemotherapy (n=376). This study also included 234 age-matched controls without cancer. Increased frailty was observed, during treatment and up to 6 months after treatment, in relation to the longitudinal decline in Functional Assessment of Cancer Therapy-Cognition and objective measures of attention and memory. Based on the findings, cognition and frailty were considered important factors to evaluate in breast cancer patients.